Broncotect®

For human respiratory wellness

Broncotect® is a selected and characterised isolate of non typeable Haemophilus influenza (NTHi) formulated to enhance T Cell migration and the immune framework. Broncotect® is ready for commercialisation as an 'Over the Counter' (OTC) or a 'Behind the Counter' (BTC) product in tablet form for sale as monthly treatments.

While there are many indirect competitor products such as vaccines, antibiotics, inhalers, cough medicines and decongestants, Broncotect® is unique with no direct competitive products that specifically promote respiratory wellness in both healthy and patients with respiratory disease.

Aerutek®

Maintaining peak condition in racehorses

Aerutek® is an advanced immunobiotic containing killed Pseudomonas aeruginosa bacteria. Trials are soon to commence to validate how Aerutek® can significantly reduce the incidence of racehorses being unable to race due to respiratory conditions. Other animals also suffer with respiratory conditions and trials will be extended to include them in the future.

While there are 31,000 thoroughbreds in training or racing each year in Australia it is estimated that 10,000 racehorses at any time cannot race due to respiratory conditions.